Journal article · 2025 · Open access
Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial
Clinical Pharmacology & Therapeutics, 119(3), 782–790 · Published 24 December 2025 · DOI 10.1002/cpt.70156
In brief
“Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial” is a 2025 journal article by Dave Singh and 9 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 11 citations as of 17 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 11
- Most cited in
- 2026 (11)
- Field-weighted impact
- 5.30
- References
- 32
- Authors
- 10
Abstract
Verekitug, a novel, high-affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). This phase 1b, double-blind, randomized, placebo-controlled, multiple ascending-dose trial assessed the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of verekitug administered subcutaneously in patients with mild-moderate asthma. Thirty-two participants were randomized in 4 placebo-controlled dosing cohorts (3 × 100-mg or 200-mg doses, once every 4 weeks; 2 × 300-mg doses, once every 12 weeks; single 25-mg dose) and observed for 32 weeks. The primary endpoint was safety; secondary endpoints were pharmacokinetics and immunogenicity. Exploratory endpoints included TSLPR occupancy and biomarker effects. Treatment-emergent adverse events were mild or moderate. Complete TSLPR occupancy was observed at the first timepoint (2 weeks post dose) and maintained for 24 weeks (doses ≥100 mg). Rapid mean reductions in fractional exhaled nitric oxide, eosinophils, and interleukin-5 (up to -54%, -65%, and -64%, respectively) were sustained up to 24 weeks (doses ≥100 mg). The mean verekitug half-life was ~20 days. Low-titer antidrug antibody response was observed in some participants, without clinically meaningful impact on pharmacokinetics, pharmacodynamics, or safety. Verekitug was generally well tolerated, with rapid, substantial, and sustained effects on asthma biomarkers. These findings support further development of verekitug for treating severe asthma, CRSwNP, and COPD.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Singh, D., Brickman, C. M., Lloyd, P. M., Kalra, A. V., Biswas, S., Sinha, A., Mulvanny, A., Sivapalasingam, S., Becker, O. M., & Deykin, A. (2025). Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial. Clinical Pharmacology & Therapeutics, 119(3), 782–790. https://doi.org/10.1002/cpt.70156
MLA 9
Singh, Dave, et al. “Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial.” Clinical Pharmacology & Therapeutics, vol. 119, no. 3, 2025, pp. 782–790. https://doi.org/10.1002/cpt.70156.
Chicago
Singh, Dave, Chaim M. Brickman, Peter M. Lloyd, Ashish V. Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, and Aaron Deykin. 2025. “Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial.” Clinical Pharmacology & Therapeutics 119 (3): 782–790. https://doi.org/10.1002/cpt.70156.
Harvard
Singh, D. et al. (2025) ‘Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial’, Clinical Pharmacology & Therapeutics, 119(3), pp. 782–790. doi:10.1002/cpt.70156.
IEEE
D. Singh et al., “Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial,” Clinical Pharmacology & Therapeutics, vol. 119, no. 3, pp. 782–790, 2025, doi: 10.1002/cpt.70156.
BibTeX
@article{singh2025verekitug,
title = {{Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial}},
author = {Singh, Dave and Brickman, Chaim M. and Lloyd, Peter M. and Kalra, Ashish V. and Biswas, Subhabrata and Sinha, Arkadeep and Mulvanny, Alex and Sivapalasingam, Sumathi and Becker, Oren M. and Deykin, Aaron},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2025},
volume = {119},
number = {3},
pages = {782--790},
doi = {10.1002/cpt.70156},
url = {https://doi.org/10.1002/cpt.70156}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- thymic stromal lymphopoietin
- monoclonal antibodies
- pharmacokinetics
- pharmacodynamics
- immunogenicity
- antidrug antibodies
- exhaled nitric oxide
- eosinophils
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Singh, D., Brickman, C. M., Lloyd, P. M., Kalra, A. V., Biswas, S., Sinha, A., Mulvanny, A., Sivapalasingam, S., Becker, O. M., & Deykin, A. (2025). Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial. Clinical Pharmacology & Therapeutics, 119(3), 782–790. https://doi.org/10.1002/cpt.70156
How many times has this paper been cited?
11 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Dave Singh, Chaim M. Brickman, Peter M. Lloyd, Ashish V. Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin.
What is the DOI of this paper?
10.1002/cpt.70156, permanently at https://doi.org/10.1002/cpt.70156. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.